NCT05983276 - Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 16, 2023

Primary Completion Date

August 28, 2030

Study Completion Date

August 28, 2031

Conditions

Ovarian Cancer

Interventions

DRUG

Decitabine

Decitabine is classified as hypomethylation agents. It works by helping the bone marrow produce normal blood cells and by killing abnormal cells in the bone marrow.

DRUG

Carboplatin

Carboplatin is classified as an alkylating agent that is used to treat ovarian cancer.

DRUG

Paclitaxel

"Paclitaxel is classified as a plant alkaloid, a taxane and an antimicrotubule agent."

DRUG

Selinexor

Selinexor is in a class of medications called selective inhibitors of nuclear export (SINE). It works by killing cancer cells.

Trial Locations (1)

60153

RECRUITING

Loyola University Medical Center, Maywood